TriPRIL CAR T Cells in Multiple Myeloma

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. * Age ≥18 years at the time of signing informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy of greater than 12 weeks * Histologically or cytologically confirmed diagnosis of relapsed/refractory multiple myeloma. Documented measurable disease includes at least one or more of the following criteria: * Serum M-protein ≥1.0 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain ≥100 mg/L with abnormal κ/λ ratio * Bone marrow plasma cells ≥30% * Relapsed/refractory multiple myeloma with at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody, as part of the same or different regimens. Note: IMWG criteria defines refractory disease as disease progression on or within 60 days of receiving a therapy Note: Induction treatment with or without hematopoietic stem cell transplant and with or without maintenance is considered a single regimen. * Adequate organ and marrow function as defined below: * O2 saturation ≥92% on room air while awake * LVEF ≥40% by ECHO or MUGA scan * ANC ≥1.0k/μl, PLT ≥50k/μl, (NOTE: Platelet transfusion not allowed within 7 days; growth factor neupogen not allowed within 7 days, neulasta within 14 days) * Cre…